Table 5 Results of the sensitivity analysis
From: Cost-effectiveness of dexamethasone compared with aflibercept in naïve diabetic macular edema
Parameter/variable | ICER |
|---|---|
Reference case | 29,002 |
No extrapolation (2-year time horizon) | 119,953 |
Extrapolation beyond 2 years | |
One-time benefit approach | 32,795 |
Beyond approach | 52,031 |
Injections taken from the PrONTO trial | 4623 |
2-year time horizon | 20,472 |
Efficacy for aflibercept from naive patients | 14,302 |
Starting age | |
58 years old | 24,553 |
90 years old | 51,798 |
Starting VA stage | |
> 20/40 | 33,653 |
≤ 20/40 to > 20/80 | 27,855 |
≤ 20/80 to > 20/200 | 26,268 |
≤ 20/200 to > 20/400 | 29,874 |
≤ 20/400 | 36,372 |
Method for utility elicitation | 36,186 |
Discounting rate | |
0% | 26,990 |
5% | 30,247 |
One-year cycle length | 30,642 |
Including indirect cost derived from family members time to assist patients | 26,900 |
Efficacy for dexamethasone from naive patients | 85,300 |